Evidence map›Paper›PMID 32954520›Full record

Observational studyEuropean journal of clinical investigation2020

The TAXINOMISIS Project: A multidisciplinary approach for the development of a new risk stratification model for patients with asymptomatic carotid artery stenosis.

Nathalie Timmerman, George Galyfos, Fragiska Sigala, Kalliopi Thanopoulou, Gert J de Borst, Lazar Davidovic, Hans-Henning Eckstein, Nenad Filipovic, Roberto Grugni, Michael Kallmayer and 12 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 12 institutions in 6 countries.

Nathalie TimmermanDepartment of Vascular Surgery, Division of Surgical Specialties, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID https://orcid.org/0000-0001-5400-4195
George GalyfosFirst Propedeutic Department of Surgery, National and Kapodistrian University of Athens, Athens, Greece.
Fragiska SigalaFirst Propedeutic Department of Surgery, National and Kapodistrian University of Athens, Athens, Greece.
Kalliopi ThanopoulouLaboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Gert J de BorstDepartment of Vascular Surgery, Division of Surgical Specialties, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
Lazar DavidovicClinic for Vascular and Endovascular Surgery, Serbian Clinical Center, Belgrade, Serbia.
Hans-Henning EcksteinClinic and Policlinik for vascular and endovascular Surgery, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Nenad FilipovicBioIRC, Research and Development Center for Bioengieering, Kragujevac, Serbia.
Roberto GrugniEngineering Ingegneria Informatica, Milan, Italy.
Michael KallmayerClinic and Policlinik for vascular and endovascular Surgery, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Dominique P V de KleijnDepartment of Vascular Surgery, Division of Surgical Specialties, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
Igor KoncarClinic for Vascular and Endovascular Surgery, Serbian Clinical Center, Belgrade, Serbia.
Michalis D MantzarisDepartment of Materials Science and Engineering, Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, Ioannina, Greece.
Elisabeth MarchalDepartment of Life Science Technologies, Imec, Leuven, Belgium.
Miltiadis MatsagkasDepartment of Vascular Surgery, Faculty of Medicine, University of Thessaly, Thessaly, Greece.
Perica MutavdzicClinic for Vascular and Endovascular Surgery, Serbian Clinical Center, Belgrade, Serbia.
Domenico PalomboDivision of Vascular and Endovascular Surgery, IRCCS Ospedale Policlinico San Martino Genoa - Italian Cardiovascular Network, Genoa, Italy.
Gerard PasterkampDivision Laboratories and Pharmacy, Laboratory of Clinical Chemistry and Hematology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
Vassiliki T PotsikaDepartment of Materials Science and Engineering, Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, Ioannina, Greece.
Evangelos AndreakosLaboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Dimitrios I FotiadisDepartment of Materials Science and Engineering, Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, Ioannina, Greece.
all partners of the TAXINOMISIS Consortium
Utrecht University · NLUniversity of Ioannina · GRAcademy of Athens · GRNational and Kapodistrian University of Athens · GRTUM Klinikum · DEUniversity of Belgrade · RSCentar za Promociju Nauke · RSEngineering (Italy) · ITIMEC · BEOspedale Policlinico San Martino · ITUniversity of Kragujevac · RSUniversity of Thessaly · GR

Funding

European Commission 755320
6 · The paper itself

Abstract

introductionAsymptomatic carotid artery stenosis (ACAS) may cause future stroke and therefore patients with ACAS require best medical treatment. Patients at high risk for stroke may opt for additional revascularization (either surgery or stenting) but the future stroke risk should outweigh the risk for peri/post-operative stroke/death. Current risk stratification for patients with ACAS is largely based on outdated randomized-controlled trials that lack the integration of improved medical therapies and risk factor control. Furthermore, recent circulating and imaging biomarkers for stroke have never been included in a risk stratification model. The TAXINOMISIS Project aims to develop a new risk stratification model for cerebrovascular complications in patients with ACAS and this will be tested through a prospective observational multicentre clinical trial performed in six major European vascular surgery centres. METHODS AND ANALYSIS: The risk stratification model will compromise clinical, circulating, plaque and imaging biomarkers. The prospective multicentre observational study will include 300 patients with 50%-99% ACAS. The primary endpoint is the three-year incidence of cerebrovascular complications. Biomarkers will be retrieved from plasma samples, brain MRI, carotid MRA and duplex ultrasound. The TAXINOMISIS Project will serve as a platform for the development of new computer tools that assess plaque progression based on radiology images and a lab-on-chip with genetic variants that could predict medication response in individual patients.

conclusionResults from the TAXINOMISIS study could potentially improve future risk stratification in patients with ACAS to assist personalized evidence-based treatment decision-making.

Indexed as

Asymptomatic DiseasesEndarterectomy, CarotidAgedAnticoagulantsBiomarkersCarotid StenosisClinical Decision RulesDisease ProgressionEndovascular ProceduresFemaleHumansHypolipidemic AgentsLab-On-A-Chip DevicesMaleMiddle AgedModels, TheoreticalAnticoagulantsBiomarkersHypolipidemic AgentsPlatelet Aggregation Inhibitorsbiomarkercarotid artery stenosispharmacogeneticsrisk stratification

Identifiers

PMID32954520
PMCPMC7757200
OpenAlexW3087528805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.